SAKK SEMI-ANNUAL MEETING



Similar documents
SAKK SEMI-ANNUAL MEETING

7 th SSHO Invitation to the. 7 th Swiss Summit on Hemato-Oncology

BREAST CANCER IN YOUNG WOMEN. OCTOBER 9 th 2015 Aula Magna UNIVERSITÀ DELLA SVIZZERA ITALIANA Lugano

ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April :10 14:20 Room C

OPEN Regional Meeting June 26 and June 27, 2015 Hyatt Regency Pier Sixty Six 2301 Southeast 17th Street Fort Lauderdale, Florida, AGENDA

Global Non-Small Cell Lung Cancer Therapeutics Market

Scientific Programme

CHEM-E4140 Selectivity 12. Pharma Business

INTERPRETING CLINICAL DATA: Highlights From ASCO 2016

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015

CURRICULUM VITAE. Paul Magnus Schneider, M.D. Professor of Surgery

«THE GENERALISTS AND SPECIALISTS FOR COMPLEX PROJECTS FROM DESIGN TO HANDOVER.»

Cancer Research in Switzerland

Promises and challenges of developing new drugs in oncology

EU Clinical Trials Register

Villejuif, Paris, France

Cancer Research in Switzerland

16 TH -17 TH INNOVATIONS IN ONCOLOGY NOVEMBER HEIDELBERG

Groundbreaking Collaborative Clinical Trial Launched

Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens

STATE OF THE ART INVITATION SATURDAY, JANUARY 30 TH, 2016 COMORBIDITIES AND ENVIRONMENTAL FACTORS INFLUENCING MULTIPLE SCLEROSIS

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct

Promises and challenges of developing new drugs in oncology

APV/IPEC Europe Excipient Conference 2014

ONCOLOGY NURSING 7 TH ESO-EONS MASTERCLASS IN March 2014 Ermatingen (Lake Constance) Switzerland MASTERCLASS

BIG DATA Driving Evidence for Healthcare Thursday, 5 March :30 17:45 Lecture Hall Pathology C

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments

Metastatic Breast Cancer - Pipeline Review, Q1 2011

KOL Insight: Non-small cell lung cancer Game changing immunotherapies to revolutionise treatment

Scientific Programme

PERSONALIZED CANCER TREATMENT A multidisciplinary event

CONSORTIUM OF SWISS ACADEMIC LIBRARIES

HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS

Direct Democracy: a distinctive feature

Pertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer

Room for your success

Employees Employees as at 31 August Employees average during the reporting period

I wish you an inspiring and successful learning experience here in Saint Petersburg. Yours Sincerely, Rachel Clark CEO, EXCEMED

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

Cancer Research in Switzerland

Primary Care Management of Colorectal Cancer

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES

ehealthinsight Series: Online Patient Recruitment Strategies

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

Gilberto de Lima Lopes, MD, MBA, FAMS Chief Medical and Scientific Officer, Oncoclinicas Group Asst. Prof. of Oncology, Johns Hopkins University

2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

Scientific Committee Hilary Calvert UCL Cancer Institute, London, United Kingdom

Gentofte Workshop. Gentofte University Hospital Copenhagen, Denmark. Basic course in CT guided lung biopsy 19th and 20th November 2012

PANAGORA PHARMA CUSTOMER EXPERIENCE SUMMIT 14

INCENTIVE COMPENSATION CONFERENCE

Ending cancer. Together.

SWISS SOCIETY FOR BIOMATERIALS AND REGENERATIVE MEDICINE NEWSLETTER

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy

Dr. Donald A. Keller, Direktor Regionalplanung Zürich und Umgebung RZU

Main Conference Agenda

European Post-Merger Integration Survey February 2010

Curriculum Vitae of Luca Gianni

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region

The Importance of the Pharmaceutical Industry for Switzerland

Avastin in Metastatic Breast Cancer

Thoracic Oncology for the Non-Oncologist

Malignant Pleural Mesothelioma - Pipeline Review, H2 2014

GOOD CLINICAL PRACTICE PROGRAM. Workshop 2006 DC THERA. November 27th 28th 2006, Dorint Hotel Erlangen, Germany

In the largest and perhaps the most ambitious collaborative

Duke Regional Diabetes Symposium 2012

Ask Us About Clinical Trials

Tennessee Chapter Scientific Meeting

Guide. Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room. NCCN.org/reimbursement

KEEPING CLINICAL TRIALS IN AUSTRALIA

Pharma RepTrak 2015 The World s Most Reputable Pharmaceutical Companies

Developed by the Clinical Trial Unit at the University Hospital Basel (CTU Basel)

Sarah A. Haecker, PhD 1782 Humboldt Avenue Minneapolis, Minnesota

International Symposium on Malignant Pleural Mesothelioma

The agency perspective: What we do and how we do it

Press Release Swiss Arbeitgeber Award 2015

ORGANIZERS Fundación para la Investigación Médica Aplicada FIMA Clínica Universidad de Navarra CUN

AUSTRIAN KNEE SYMPOSIUM Sports Medicine Traumatology Prostheses Level: Advanced

Cancer Research in Switzerland

9 th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) 9th International Symposium

The Human Right to Science: New Directions for Human Rights in Science

Key Staff Members EXECUTIVE TEAM Nancy Price Mendenhall, MD Medical Director Stuart Klein, MHA Executive Director Zuofeng Li, DSc Physics Director

CURRICULUM VITAE Conches (Swtzerland) (personal assistant) Private phone number

Cachexia and Nutrition in Advanced Cancer Patients: a Multidisciplinary Approach Chairs: M.S. Aapro, CH J. Herrstedt, DK F.

Transcription:

SAKK SEMI-ANNUAL MEETING THURSDAY, JUNE 25, 2015 AND FRIDAY, JUNE 26, 2015 AT THE ZURICH MARRIOTT HOTEL NEUMUEHLEQUAI 42, 8006 ZURICH SAKK COORDINATING CENTER EFFINGERSTRASSE 40 3008 BERNE T +41 31 389 91 91 F +41 31 389 92 00 We bring progress to cancer care

General Information WELCOME NOTE Berne, May 2015 Dear friends of SAKK, dear madam or sir, dear colleagues It is our pleasure to invite you to the June semi-annual meeting to be held at the Marriott Hotel at the river banks in Zurich. Please find hereafter the program, general information and registration details. 2015 is an exceptional year as we are celebrating the 50 th anniversary of our SAKK Network. This is also reflected in the program as we will be looking back on the scientific, political and ethical change in clinical research. But of course we will also discuss the future perspectives on civic, regulatory and research challenges and let patient representatives share their views how they want to actively be involved in clinical research. Not only the jubilee program promises insights, also our specialist groups have invited guests to discuss with them their fields of specialty. Please consult the scientific program for further information. Furthermore, it is our pleasure to draw your attention to the Satellite Symposium, organized by Roche Pharma (Schweiz) AG with a focus on the next level in melanoma therapy opening a new paradigm of cancer therapy. For the first time we will display poster presentations and are curious how they will be met by our audience. Therefore, please make sure to visit the «Time Square» and have a look at them. Last but not least we proudly present the SAKK / Dr. Paul Janssen Fellowship as well as the SAKK / Pfizer Award to the next generation of researchers. Traditionally, SAKK partner organizations, such as NICER, OncoCampus and industry representatives use our platform to meet as well. We will again have two eventful days which will bring progress to cancer care. We look forward to welcoming you in Zurich. Sincerely SAKK Coordinating Center Prof. Dr. Beat Thürlimann President Dr. Peter Brauchli CEO SAKK Bern page 2 / 8

SCIENTIFIC PROGRAM THURSDAY, JUNE 25, 2015 General Information 08.30 09.00 Registration and Welcome Coffee Time Square, 2 nd fl. 09.00 10.00 Section Outcome Research Chair: Bernhard Pestalozzi, University Hospital Zurich 09.00 11.00 WG Symptom Control and Palliative Cancer Care Chair: Florian Strasser, Cantonal Hospital St. Gallen 09.00 12.00 PG Lung Cancer ** Chair: Oliver Gautschi, Cantonal Hospital Luzern 09.00 10.00 open session 10.00 12.00 closed session PG Gastro-Intestinal Cancer & Section Surgery, joint meeting ** Co-Chairs: Michael Montemurro, IOSI, Bellinzona Walter R. Marti, Cantonal Hospital Aarau 09.00 10.00 open session 10.00 12.00 closed session Tourbillon, 4 th fl. Index A, ground fl. Pendulum, 4 th fl. Millennium B, 2 nd fl. 09.00 17.30 NICER, closed session in the Main Building Annum, 1 st floor 10.15 12.00 SAKK Info for CRCs and Trial Nurses Chair: Peter Durrer, SAKK CC WG Sarcoma Chair: Christian Rothermundt, Cantonal Hospital St. Gallen Decade, 1 st fl. Tourbillon, 4 th fl. 12.00 12.45 Lunch Buffet at Time Square and Millennium Main Building 2 nd fl 12.45 14.00 SAKK / Dr. Paul Janssen Fellowship SAKK / Pfizer Award SAKK 50 Years Symposium: 13.00 Welcome and Forecast Anniversary Year Prof Dr Beat Thürlimann, President SAKK Century AB, 2 nd fl. 13.05 Walk of fame? 50 Years of Clinical Cancer Research Looking back on the Scientific, Political and Ethical Change in Cancer Research Prof Dr Franco Cavalli, Bellinzona 13.20 How Patient Advocacy Groups contribute to Clinical Cancer Research How Patients Contribute to Clinical Research in the Future Markus Wartenberg, Lebenshaus 13.35 Back to the future: example pancreatic carcinoma Achievements and Future Challenges Dr Michael Montemurro, Bellinzona 13.50 Discussion and Closing Words Prof Dr Beat Thürlimann, President SAKK 14.00 14.15 Coffee break at Time Square and Millennium Main Building 2 nd fl. SAKK Bern page 3 / 8

Cont. Scientific Program 14.15 15.45 Satellite Symposium: Roche Pharma (Schweiz) AG The Next Level in Melanoma Therapy: Overcoming Resistance & Combining Targeted- and Immunotherapies Chair: Roger von Moos - see separate Program Century AB, 2 nd fl. 15.45 16.00 Coffee break at Time Square and Millennium Main Building 2 nd fl 16.00 17.30 Section Surgery Day-Chair: Christoph Kettelhack, University Hospital Basel 16.00 18.00 WG Head and Neck Cancer Chair: Frank Zimmermann, University Hospital Basel 16.00 18.15 PG Urogenital Tumors ** Chair: Richard Cathomas, Cantonal Hospital Grison 16.00 16.30 open session 16.30 18.15 closed session PG New Anticancer Drugs ** Chair: Markus Joerger, Cantonal Hospital St. Gallen 16.00 16.30 open session, with special guest Dr. Sabine Wittemer-Rump, Director Experimental Medicine Oncology, Bayer Pharma Ltd, Berlin, Germany Innovative Oncology in Development at Bayer Pharma 16.30 18.15 closed session 16.00 18.00 WG Central Nervous System Tumors Chair: Andreas Hottinger, CHUV, Lausanne 17.45 19.15 Section Network Cancer Predisposition Testing and Counselling (open session) Chair: Pierre Chappuis, University Hospital Geneva With special guest Prof. Dr. Maria C. Katapodi, Institute of Nursing, Science Faculty of Medicine, University of Basel Feasibility of using a cancer registry for cascade screening of women at-risk for breast cancer 18.00 19.30 Section Radio Oncology, closed session Chair: Ludwig Plasswilm, Cantonal Hospital St. Gallen Pendulum, 4 th fl. Tourbillon, 4 th fl. Millennium B, 2 nd fl. Decade, 1 st fl. Index A, ground fl. Annum, 1 st floor Index B, ground fl. ** open and closed session FRIDAY, JUNE 26, 2015 08.30 09.00 Registration and Welcome Coffee, Main Building Time Square, 2 nd fl. 09.00 11.00 WG Gynecological Cancer Chair: Cristiana Sessa, IOSI, Bellinzona Joint Meeting: PG Leukemia & PG Lymphoma ** Co-Chairs: Georg Stüssi, IOSI, Bellinzona & Emanuele Zucca, IOSI, Bellinzona 09.00 10.00 open session, with special guest Ass. Prof. Davide Rossi, University of Piemonte Orientale Amedeo Avogadro, Novara, Italy The clinical implications of gene mutations in CLL 10.00 11.00 closed session Century A, 2 nd fl. Century B, 2 nd fl. SAKK Bern page 4 / 8

Cont. Scientific Program 09.00 11.00 WG Imaging in Diagnostic and Therapy Monitoring ** Chair: Johannes Heverhagen, Insel Hospital, Bern 09.00 09.25 open session 09.25 11.00 closed session 11.00 11.30 Coffee break & Lunch Bags pick-up, at Time Square and Millennium 11.30 14.15 cont. Joint Meeting PG Leukemia & PG Lymphoma, closed session only Co-Chairs: Georg Stüssi, IOSI, Bellinzona & Emanuele Zucca, IOSI, Bellinzona 11.30 15.30 PG Breast Cancer ** Chair: Thomas Ruhstaller, Cantonal Hospital St. Gallen 11.30 12.30 open session, with special guest Steven Shak, M.D., Chief Scientific Officer Genomic Health, Inc. Redwood City, CA, USA Development and Future of Genomic Tests in Oncology 12.30 15.30 closed session 15.30 16.30 SAKK 21/12 Investigator s Meeting Chair: Martin Zweifel, Insel Hospital, Bern 14.00 16.00 Oncocampus (by invitation only) Chair: Heinrich Walt, University Hospital Zurich Decade, 1 st fl. 2 nd fl. Century B, 2 nd fl. Millennium B, 2 nd fl. Annum, 1 st floor Index AB, ground fl. ** open and closed session POSTER SESSION For the first time, there will be the following posters (in alphabetical order) on display at the «Time Square» for the duration of the meeting: Comparison of design options for phase IB clinical trials in oncology: simulation results M. Bigler, St. Hayoz, A. Xyrafas, D. Klingbiel Delivery of Health Care at the End of Life in Cancer Patients from Four Swiss Cantons (SAKK 89/09) K. Matter-Wastra, R. Achermann, R. Rapold, D. Klingbiel, A. Bordoni, S. Dehler, G. Jundt, I. Konzelmann, K. Clough-Gorr, T. Szucs, M. Schwenkglenks, B.C. Pestalozzi Do cancers located at the hepatic or splenic flexure have a worse outcome compared to other colon cancers? S. Käser, D. Dietrich, C. Maurer Does the radicality and quality of colorectal cancer surgery depend on the patient s age? S. Käser, D. Dietrich, C. Maurer Effect of one-patient clusters on power in cluster-randomized trials St. Hayoz, D. Klingbiel Health economic analysis of the randomized multicenter phase II trial SAKK 77/08: sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC) K. Matter-Walstra M. Schwenkglenks, Q. Li, I. Cvijetic, B. Tschanz, P. Samaras, P. Saletti, A.D. Roth, D. Horber, D. Koeberle SAKK Bern page 5 / 8

Cont. Scientific Program Health economic evaluation of: Bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced breast cancer: A multicenter, randomized phase III trial - SAKK 24/09 K. Matter-Walstra, M. Bigler, M. Schwenkglenks, D. Bärtschi, J. Brechbühl, U. Hasler-Strub, R. von Moos, A. Müller, R. Winterhalder, Chr. Rochlitz INDIVIDUAL MEETING AGEND AS Please make sure to check out the individual meeting agendas of each group which will be available on our website http://sakk.ch/hjv-agendas latest two weeks prior to the meeting. FLOORPLAN MARRIOTT SAKK Bern page 6 / 8

General Information SAKK AT A GLANCE Organisation Non-profit institution, association, founded in 1965 President Prof. Dr. med. Beat Thürlimann, Head Physician Breast Center St. Gallen Vice-President PD Dr. med. Roger von Moos, Head Physician Oncology/Hematology, Chur CEO Dr. sc nat Peter Brauchli Members Cantonal Hospital Aarau, Cantonal Hospital Baden, University Hospital Basel; University Hospital Berne, Hospital Center Bienne, Cantonal Hospital Fribourg, University Hospital Geneva, Cantonal Hospital Grisons, Clinik Hirslanden, Zurich, Cantonal Hospital St. Gallen, Hospital STS Ltd. Thun, Hospital Thurgau AG, IOSI (Istituto Oncologico della Svizzera Italiana) Ticino, Hospital Valais, University Hospital Vaud, Cantonal Hospital Winterthur, Cantonal Hospital Luzern, City Hospital Triemli Zurich, University Hospital Zurich Assoc. Members St. László Teaching Hospital, Budapest, Hungary; Centre Paul Strauss, Strassbourg, France; University Hospitals Freiburg, Freiburg i.b, Germany SAKK Amgen Switzerland AG, ARIAD Pharmaceuticals, Astellas Pharma AG, Industry Pool AstraZeneca AG, Bayer (Schweiz) AG, Boehringer Ingelheim (Schweiz) GmbH, Bristol-Myers Squibb SA, Celgene GmbH, Eli Lilly (Suisse) SA, Genomic Health Intl Sàrl, Janssen-Cilag AG, Lipomed AG, MSD Merck- Sharp& Dhome AG, Merck (Schweiz) AG, Mundipharma Medical Company, Novartis Pharma (Schweiz) AG, Pfizer AG, PharmaMar AG, Pierre Fabre Pharma AG, Roche Pharma (Schweiz) AG, Sandoz Pharmaceuticals AG, Sanofi-Aventis (Suisse) SA, Spectrum Pharmaceuticals, Takeda Pharma AG, Teva Pharma AG, Vifor AG Our sincere thanks go to the members of the SAKK Industry Pool. Without the regular financial support from these pharmaceutical companies it would not be possible to hold the SAKK Semi-Annual Meetings on the current scale! We appreciate your support. NEXT SEMI-ANNUAL MEETINGS 2015: Marriott, ZH 2016: Marriott, ZH 2017: Marriott, ZH 2018: Marriott, ZH June 30/July 1 June 29/30 June 28/29 Nov 19/20 Nov 24/25 Nov 23/24 Nov 22/23 Please note, our events always take place in week 26 (June) and week 47 (November). SAKK Bern page 7 / 8

GENERAL INFORMATION General Information HOW TO GET THERE The Marriott is in a central location, a mere nine minute stroll along the banks of the river Limmat from Zurich s main train station. You may also use tram N 11 (direction Rehalp) or 14 (direction Seebach) to get to the stop «Beckenhof» two minutes from the hotel. ACCREDITATION The following associations grant credits: SGC-SSC : 15 credits (Thu: 9 pts./fri: 6 pts.) SGR-SSR : 12 credits (Thu: 6 pts./fri: 6 pts.) SGMO : 16 credits (Thu: 10 pts./fri:6 pts.) SGH-SSH : 5 credits (Thu: 1 pt./fri: 4 pts.) SRO-SSRO:16 credits (4 pts. per half-day) PARKING The hotel has its own parking at CHF 4/h or CHF 24 for the day. You may also use the parking Sihlquai in in the vicinity of the hotel. REGISTRATION Please register by Thursday, June 18, 2015 online at http://sakk.ch/hjv-registration, or by e-mail to events@sakk.ch. ORGANISATION SAKK Coordinating Center Effingerstrasse 40 3008 Bern T +41 31 389 91 91 F +41 31 389 92 00 Contact: Iris Meyer & Caroline Kaminski Event Managers T +41 31 389 78 Tram stop 11,14 Marriott Sihlquai 41, 8005 Zurich SAKK Bern page 8 / 8